amlodipine

(redirected from Olmesartan medoxomil)
Also found in: Medical.
Translations

amlodipine

n amlodipino, amlodipina
References in periodicals archive ?
for one, this month introduced olmesartan medoxomil tablets, 5 mg, 20 mg and 40 mg.
M2 PHARMA-July 18, 2017-FDA approves Alembic Pharmaceuticals' ANDA for Olmesartan Medoxomil and Amlodipine tablets
Glenmark Pharmaceuticals has received final approval from the US health regulator for Amlodipine and Olmesartan Medoxomil tablets, used in the treatment of hypertension.
M2 EQUITYBITES-May 26, 2017-Glenmark Pharma gains US FDA approval for its blood pressure generic Olmesartan Medoxomil
2 -- Ajanta Pharma Limited, announces today US FDA* approval and launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc.
Olmesartan medoxomil (trade name Benicar), the prodrug of olmesartan, is an angiotensin II receptor blocker (ARB) that was approved for use in the United States as an antihypertensive medication in 2002.
5 mg/d; olmesartan medoxomil, 40 mg/d; aspirin, 81 mg/d; simvastatin, 10 mg/d; eszopidone, 3 mg at bedtime; and amlodipine, 5 mg at bedtime.
It combines olmesartan medoxomil (which blocks angiotensin II receptors), amlodipine (which inhibits the entrance of calcium into the blood vessel walls), and hydrochlorothiazide (a diuretic which reduces water volume in the blood).
Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide.
The aggressive use of statins and other medications is critical in helping to reverse atherosclerosis (the angiotensin receptor blocker olmesartan medoxomil [Benicar] may be effective in reversing vascular damage in patients with high blood pressure, according to a study reported in the June Journal of the American Society of Hypertension).
3%) drugs were registered to treat cardiovascular conditions: bosentan (C02KX01), barnidipine (C08CA12), midodrine (C01CA17), dofetilide (C01BD04), ezetimibe (C10AX09), levosimendan (C01CX08), olmesartan medoxomil (C09CA08), and rosuvastatin (C10AA07).
Elsewhere in the regional list, drug group GlaxoSmithKline said it had entered into an agreement with Japanese company Daiichi Sankyo to sell its hypertension drug Olmesartan Medoxomil in India.